ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study.
Cameron Crowell, Nikhil P Mankuzhy, Julie Bennett, Pratiti Bandopadhayay, Dominik Sturm, Adam L Green, Tejpal Gupta, Abhishek Chatterjee, Sridhar Epari, Girish Chinnaswamy and 53 more
Abstract readMulticenter Study
In one paragraphArticle in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
63 authors.
Nikhil P MankuzhyDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-9004-7598 Pratiti BandopadhayayDana-Farber/Boston Children's Cancer and Blood Disorder Center , Boston, Massachusetts.ORCID 0000-0002-4175-4760 Adam L GreenMorgan Adams Foundation Pediatric Brain Tumor Research Program, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0002-4469-2358 Magimairajan Issai VananDepartment of Pediatrics and Child Health, University of Manitoba, Winnipeg, Canada.ORCID 0000-0003-2015-0615 Jacquelyn JonesDana-Farber/Boston Children's Cancer and Blood Disorder Center , Boston, Massachusetts.ORCID 0009-0001-3762-0444 Sébastien PerreaultDivision of Child Neurology, Department of Neurosciences, CHU Sainte-Justine, Montréal, Canada.ORCID 0000-0002-4417-7698 Charlotte FeddersenMorgan Adams Foundation Pediatric Brain Tumor Research Program, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0009-0005-1014-6155 Miriam Pavon-MengualDepartment of Pediatric Oncology, Hospital Sant Joan de Déu Barcelona, Barcelona, Spain.ORCID 0009-0004-9983-0780 Olivia VizziniDana-Farber/Boston Children's Cancer and Blood Disorder Center , Boston, Massachusetts.ORCID 0009-0004-3488-0920 Michal ZápotockýDepartment of Pediatric Hematology and Oncology, Motol University Hospital, Prague, Czechia.ORCID 0000-0002-9013-2546 Jordan R HansfordMichael Rice Centre for Hematology and Oncology, Women's and Children's Hospital, Adelaide, Australia.ORCID 0000-0001-7733-383X Laveniya SatgunaseelanDepartment of Neuropathology, Royal Prince Alfred Hospital, Camperdown, Australia.ORCID 0000-0002-7435-0834 Louise LudlowMurdoch Children's Research Institute , Royal Children's Hospital, Parkville, Australia.ORCID 0009-0000-0001-8946 David EisenstatMurdoch Children's Research Institute , Royal Children's Hospital, Parkville, Australia.ORCID 0000-0002-5976-0798 Dong-Anh Khuong-QuangMurdoch Children's Research Institute , Royal Children's Hospital, Parkville, Australia.ORCID 0000-0001-6305-7790 Nicolas AndréDepartment of Pediatric Hematology, Immunology and Oncology, Timone Hospital APHM, Marseille, France.ORCID 0000-0002-6786-4968 Aimee ChanDivision of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.ORCID 0000-0002-1978-2853 Mary Jane Lim-FatDivision of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.ORCID 0000-0002-4317-5770 Sara KhanDivision of Hematology/Oncology and Bone Marrow Transplantation, Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio.ORCID 0000-0001-8206-4590 Mariah Wright-NadkarniDivision of Hematology/Oncology and Bone Marrow Transplantation, Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio.ORCID 0000-0001-6163-6991 Ralph SalloumDivision of Hematology/Oncology and Bone Marrow Transplantation, Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio.ORCID 0000-0001-9437-0616 Robert T GalvinDivision of Pediatric Hematology and Oncology, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0001-7139-9707 Cynthia HawkinsDepartment of Laboratory Medicine and Pathobiology, The Hospital for Sick Children, Toronto, Canada.ORCID 0000-0003-2618-4402 Brandon S ImberDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-1281-5915 Matthias A KarajannisDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-7151-6528 Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MIWK Health Centre (IWK) 1028593IWK Health Centre (IWK) 1028902NCI NIH HHS P30 CA008748
6 · The paper itselfAbstract
purposeKnowledge of prognostic factors and long-term survival in patients with diffuse hemispheric glioma, H3 G34-mutant (DHG, H3 G34), remains limited in this tumor with a poor prognosis. EXPERIMENTAL
designThis retrospective, multi-institutional study investigated prognostic variables for patients with DHG, H3 G34, and their association with progression-free survival (PFS) and overall survival (OS). Uni- and multivariable Cox proportional hazard models were applied with multiple imputed datasets.
resultsA total of 153 patients (142 G34R, 9 G34V, 2 via DNA methylation) were included. The median age at diagnosis was 17 years (range, 2-45). Initial gross/near total resection (GTR/NTR) was achieved in 43% of patients. Radiation was given in 91% (85% focal irradiation), and initial chemotherapy was given in 87% [70% temozolomide-based (TMZ), 25% TMZ/lomustine, 5% non-TMZ]. Median OS was 24 months [interquartile range (IQR), 22-28] with a median PFS of 14 months (IQR, 12-19). Twelve patients (8%) were found to be long-term survivors (≥5 years). Exploratory multivariable analysis showed that adjuvant radiotherapy [HR, 0.076; 95% confidence interval (CI), 0.033-0.17] and achieving GTR/NTR compared with < NTR (HR, 0.51; 95% CI, 0.33-0.78) were associated with improved PFS. Multivariable analysis showed improved OS with increasing age at diagnosis (HR, 0.70; 95% CI, 0.57-0.87), initial radiotherapy (HR, 0.38; 95% CI, 0.15-0.96), and initial GTR/NTR compared with < NTR (HR, 0.60; 95% CI, 0.37-0.97).
conclusionsThis cohort highlights prognostic factors for patients with DHG, H3 G34, and describes relapse patterns and therapy approaches. Clinical trials and prospective registries are needed to improve outcomes.
Indexed as
Biomarkers, TumorBrain NeoplasmsGliomaHistonesMutationAdolescentAdultChildChild, PreschoolDNA MethylationFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesBiomarkers, TumorHistones
Identifiers
PMID41801141
PMCPMC13223545
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390